Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases

被引：47

作者：

Guan, Shi-Yang ^{[1
,2
]}

Leng, Rui-Xue ^{[1
,2
]}

Khan, Muhammad Imran ^{[1
,2
]}

Qureshi, Humera ^{[1
,2
]}

Li, Xiang-Pei ^{[3
]}

Ye, Dong-Qing ^{[1
,2
]}

Pan, Hai-Feng ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China

[2] Anhui Med Univ, Anhui Prov Lab Populat Hlth & Major Dis Screening, 81 Meishan Rd, Hefei, Anhui, Peoples R China

[3] Anhui Prov Hosp, Dept Rheumatol & Immunol, 17 Lujiang Rd, Hefei, Anhui, Peoples R China

来源：

INFLAMMATION | 2017年 / 40卷 / 01期

基金：

中国国家自然科学基金;

关键词：

interleukin-35; Th17; cells; Treg cells; therapeutic agent; autoimmune diseases; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MESENCHYMAL STEM-CELLS; B-CELLS; TH17/TREG IMBALANCE; INDUCED ARTHRITIS; IMMUNE-RESPONSES; MURINE MODEL; IL-35; CYTOKINE;

D O I：

10.1007/s10753-016-0453-9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.

引用

页码：303 / 310

页数：8

共 50 条

[1] Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases
Shi-Yang Guan
Rui-Xue Leng
Muhammad Imran Khan
Humera Qureshi
Xiang-Pei Li
Dong-Qing Ye
Hai-Feng Pan
Inflammation, 2017, 40 : 303 - 310
[2] Interleukin-35 in autoimmune dermatoses: Current concepts
Xie, Yuming
Zhang, Huilin
Huang, Junke
Zhang, Qing
OPEN MEDICINE, 2022, 17 (01): : 599 - 610
[3] Role of interleukin-35 in cardiovascular diseases
Zhang, Jialun
Xing, Yue
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2023, 97 (02)
[4] The possible role of interleukin-35 and its therapeutic potential in pemphigus
Tavakolpour, Soheil
Kheiry, Forough
Mirsafaei, Hajar Sadat
Akhlaghdoust, Meisam
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 42 : 11 - 17
[5] Interleukin-35: The Future of Hyperimmune-Related Diseases?
Ye, Sunyi
Wu, Jian
Zhou, Lin
Lv, Zhen
Xie, Haiyang
Zheng, Shusen
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2013, 33 (06) : 285 - 291
[6] The immunomodulatory role of interleukin-35 in fibrotic diseases
Luo, Man
Peng, Hong
Chen, Ping
Zhou, Yong
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (04) : 431 - 439
[7] Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases
Ye, Cheng
Yano, Hiroshi
Workman, Creg J.
Vignali, Dario A. A.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2021, 41 (11) : 391 - 406
[8] Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer
Pylayeva-Gupta, Yuliya
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4973 - 4978
[9] Therapeutic potential of interleukin-2 in autoimmune diseases
Yuan, Yeshuang
Kolios, Antonios G. A.
Liu, Yudong
Zhang, Bo
Li, Hao
Tsokos, George C.
Zhang, Xuan
TRENDS IN MOLECULAR MEDICINE, 2022, 28 (07) : 596 - 612
[10] Systematic Review of Interleukin-35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention
Li, Kai
Feng, Jie
Li, Meng
Han, Leilei
Wu, Yanqing
MEDIATORS OF INFLAMMATION, 2025, 2025 (01)

← 1 2 3 4 5 →